Retatrutide and Andrew Huberman: what the Stanford neuroscientist says about this investigational triple-agonist, how trials compare, and what is unknown.
Andrew Huberman has discussed retatrutide on the Huberman Lab podcast as an investigational, next-generation weight loss drug rather than an approved medicine. He covers it the way a scientist explains published research, not the way a physician writes a prescription. Retatrutide and Andrew Huberman is a search that usually comes down to one question: is his take worth acting on, and the answer is that his commentary is educational only.
Who Andrew Huberman Is and Why People Search His Name
Andrew Huberman is a neuroscientist and tenured associate professor at Stanford University School of Medicine. He hosts the Huberman Lab podcast, which consistently ranks among the most listened-to health and science shows in the United States.
His episodes on hunger, appetite, and metabolic health often touch on GLP-1 receptor agonists, so listeners naturally look for his perspective whenever a new drug like retatrutide makes headlines.
He is not an obesity medicine specialist, and he does not prescribe these drugs. There is no public indication that he is affiliated with Eli Lilly, the company developing retatrutide, so his commentary should be read as a summary of already-public research.
What Huberman Actually Says About Retatrutide
When retatrutide comes up, it usually appears inside a larger conversation about incretin-based drugs and body weight regulation. A few themes repeat across those discussions.
- It is a triple agonist. Retatrutide targets three receptors at once: GIP, GLP-1, and glucagon. That third target is what separates it from semaglutide and tirzepatide.
- It is still experimental. Huberman frames retatrutide as a Phase 3 candidate, not a product you can pick up at a pharmacy.
- Drugs do not replace behavior. He consistently pairs drug talk with resistance training, adequate protein, sleep, and daylight exposure — habits that help protect lean mass during rapid weight loss.
- Risk belongs in the conversation. He notes that long-term safety data for retatrutide do not exist yet because the drug is so new.
Some viewers wonder whether is retatrutide a glp-3, but that is not an official pharmacological category. Retatrutide is classified as a triple receptor agonist, and "GLP-3" is internet shorthand rather than a recognized drug class.
Retatrutide Compared With Other Incretin Drugs
Questions like cagrilintide vs retatrutide come up constantly because several experimental drugs are moving through trials at the same time. The table below shows where each one stands.
| Drug | Receptor targets | US status | Trial dosing |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | FDA-approved for weight management | Weekly injection, up to 2.4 mg |
| Tirzepatide (Zepbound) | GIP + GLP-1 | FDA-approved for weight management | Weekly injection, up to 15 mg |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational | Weekly injection, up to 12 mg in Phase 2 |
| Cagrilintide | Amylin analog (studied with semaglutide) | Investigational | Weekly injection |
The practical difference is approval status. Semaglutide and tirzepatide can be prescribed today, while retatrutide and cagrilintide cannot. An approved GIP/GLP-1 combination like tirzepatide is also a useful reference point, because it shows what those comparisons are really measuring: average weight loss, tolerability, and durability over time.
What the Human Trials Show
The main reason Huberman and other science communicators mention retatrutide is the Phase 2 data. In a 48-week trial published in the New England Journal of Medicine in 2023, participants taking the highest dose lost roughly 24% of their body weight on average, while the placebo group lost about 2%.
A Phase 3 program called TRIUMPH is now running, with studies in people who have obesity, type 2 diabetes, and related conditions such as knee osteoarthritis. Full results are expected over the next few years.
When people ask how long does retatrutide take to work, the honest answer is that appetite changes often appear within the first few weeks of dosing, but meaningful weight change accumulates over months. Phase 2 results were measured at 48 weeks, and longer-term data are still pending.
Dosing, Injection, and Availability
In trials, retatrutide is given as a weekly subcutaneous injection, usually starting at a low dose and escalating slowly to limit side effects. Study doses have ranged from 1 mg to 12 mg.
There is no retatrutide brand name yet, because the drug has no approved commercial product or label. Eli Lilly has not announced branded packaging or pricing for the United States.
Official guidance on retatrutide how to inject does not exist, because there is no approved label or prescribing information. Any website selling "retatrutide" today is not selling an approved medicine, and research-grade or compounded vials are unregulated, which means purity, sterility, and actual dose are all unverified.
Safety, Side Effects, and Legal Status
Reported side effects in trials look similar to other incretin drugs: nausea, diarrhea, vomiting, and constipation, usually mild to moderate and worst during dose increases. Researchers have also tracked increases in resting heart rate and a small number of gallbladder issues.
Retatrutide is not FDA-approved for human use in the United States, so no legally prescribed version exists here. Long-term effects on the heart, thyroid, and pancreas remain unknown.
Anyone considering an incretin-based drug should talk with a physician who can review their medical history, current medications, and risk factors before making a decision.
Key Takeaways for Listeners
- Andrew Huberman discusses retatrutide as an investigational drug, and his commentary is education rather than medical advice.
- Retatrutide is a triple agonist that targets GIP, GLP-1, and glucagon receptors.
- Retatrutide is not FDA-approved for human use in the United States.
- Phase 2 data showed roughly 24% average body weight loss at 48 weeks with the 12 mg dose.
- Anyone interested in incretin-based weight loss should consult a licensed healthcare professional.
Frequently Asked Questions
Did Andrew Huberman recommend retatrutide?
No. Huberman has discussed retatrutide as an investigational triple-agonist in the context of obesity research, and he does not prescribe or endorse the drug. There is no public indication that he has a financial relationship with Eli Lilly, the manufacturer. His commentary summarizes published trial data and should not be treated as medical advice.
Is retatrutide FDA approved?
No. Retatrutide is not FDA-approved for human use in the United States and is currently being studied in the Phase 3 TRIUMPH program. It cannot be legally prescribed or dispensed by a pharmacy. Products marketed online as retatrutide are unregulated research chemicals, not approved medicines.
How much weight loss does retatrutide cause?
In a 48-week Phase 2 trial published in 2023, participants on the highest 12 mg dose lost about 24% of their body weight on average, compared with roughly 2% for placebo. Those results are promising but come from a single mid-stage study. Phase 3 results will determine whether the drug is approved.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.